polyneuropathy

(redirected from amyloid polyneuropathy)
Also found in: Medical.
Related to amyloid polyneuropathy: amyloidosis
Translations

pol·y·neu·rop·a·thy

n. polineuropatía, enfermedad que afecta varios nervios a la vez.

polyneuropathy

n polineuropatía
References in periodicals archive ?
Pfizer Inc announced the publication of a new interim analysis of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary transthyretin amyloid polyneuropathy (TTR-FAP) and was well tolerated, with no unexpected side effects.
M2 PHARMA-September 1, 2017-Pfizer Publishes Long-Term Data Analysis Showing Tafamidis Delays Progression of Hereditary Transthyretin Amyloid Polyneuropathy
This study will enable to know the reasons why subjects at-risk for Familial Amyloid Polyneuropathy (FAP), Huntington's Disease (HD), and Machado-Joseph Disease (MJD) want to perform the PST and compare the results with the motivations of the subjects atrisk for Hereditary Hemochromatosis (HH) which also wish to carry the presymptomatic testing (PST).
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is a very rare life-threatening disorder and reported only in a few countries.
Global Markets Direct's, 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2015', provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline.
Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.
has earned a $15 million milestone payment from GSK related to advancing the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Thursday the receipt of USD18m milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
UKPRwire, Tue Aug 06 2013] Global Markets Direct's, 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline.
to treat transthyretin amyloid polyneuropathy, a fatal disorder of the nervous system that affects about 8,000 people worldwide, Labaudiniere said.
Late-onset familial amyloid polyneuropathy type I (Transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan.
Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation.